Fenofibrate, an FDA-approved drug commonly used to treat high cholesterol, activated support cells around sensory neurons in mouse models of spinal cord injury, helping them regrow twice as fast as a placebo.
Both the ApoE genotype and the sex of the mouse impacted the manner in which the animals with spinal cord injury responded to hypoxia treatment. Females with the ApoE e4 gene had a negative response to intermittent hypoxia.
People with spinal cord injuries have the same brain activity during processing speed tasks as healthy older adults. The findings suggest the theory of accelerated cognitive aging following SCI is correct.
Research shows it is possible to stimulate stem cells in the spinal cord to produce large amounts of new oligodendrocytes.
Axon regeneration and dramatic improvements in functional recovery occurred when lactate was applied to damaged neural tissue. Treatment with lactate also significantly improved locomotion and restored some walking capability in mouse models of SCI.
A newly designed synthetic compound could act as a prototype for a novel class of drugs to treat neurological damage.
The application of synchronized transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) restored the ability to walk in a patient with spinal cord injury.